Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma

verfasst von: Yousri M. Hussein, Amal F. Ghareib, Randa H. Mohamed, Mohamed I. Radwan, Wael H. Elsawy

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The dissemination of hepatocellular carcinoma (HCC) cells into the circulation plays a critical role in post-operative recurrence and metastasis. Early detection of metastatic tumor cells is critical to identify HCC patients at high risk of relapse. MAGE-3 and -4 genes were evaluated by reverse transcription polymerase chain reaction for the possibility of using them as new markers for early detection of metastases in 160 chronic HCV Egyptian patients, 115 of them were complicated with HCC. The expressions of MAGE-3 and MAGE-4 mRNA in peripheral blood of patients with metastatic HCC were 36 and 52%, respectively. While the expressions of MAGE-3 and MAGE-4 mRNA in peripheral blood of patients with localized HCC were 12.5 and 15%, respectively. Moreover, at least one type of mRNA was found in the peripheral blood of 68% of the metastatic HCC patients and in 20% of the localized HCC patients. While neither the controls nor the cirrhotic patients show expression of MAGE-4 mRNA in their peripheral blood. MAGE-3 and MAGE-4 may be a promising diagnostic tool for monitoring the prognosis of HCC patients and early detection of occult hematogenous metastasis of HCC.
Literatur
1.
Zurück zum Zitat Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellula carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg. 2002;137:94–9.PubMedCrossRef Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T, et al. Intrahepatic recurrences of hepatocellula carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg. 2002;137:94–9.PubMedCrossRef
2.
Zurück zum Zitat Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90(4):803–16.PubMedCrossRef Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am. 2010;90(4):803–16.PubMedCrossRef
3.
Zurück zum Zitat Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer. 2002;86:110–116. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer. 2002;86:110–116.
4.
Zurück zum Zitat Wong IH, Leung T, Ho S, Lau WY, Chan M, Johnson PJ. Semiquantitation of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer. 1997;76(5):628–33.PubMedCrossRef Wong IH, Leung T, Ho S, Lau WY, Chan M, Johnson PJ. Semiquantitation of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer. 1997;76(5):628–33.PubMedCrossRef
5.
Zurück zum Zitat Suzuki K, Tsujitani S, Konishi I, Yamaguchi Y, Hirooka Y, Kaibara N. Expression of MAGE genes and survival in patients with hepatocellular carcinoma. Int J Oncol. 1999;15:1227–32.PubMed Suzuki K, Tsujitani S, Konishi I, Yamaguchi Y, Hirooka Y, Kaibara N. Expression of MAGE genes and survival in patients with hepatocellular carcinoma. Int J Oncol. 1999;15:1227–32.PubMed
6.
Zurück zum Zitat Baker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67:705–12.CrossRef Baker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67:705–12.CrossRef
7.
Zurück zum Zitat Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem. 2003;278 (12):10668–10674. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem. 2003;278 (12):10668–10674.
8.
Zurück zum Zitat Kariyama K, Higashi T, Kobayashi Y, Nouso K, Nakatsukasa H, Yamano T, et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer. 1999;81(6):1080–7.PubMedCrossRef Kariyama K, Higashi T, Kobayashi Y, Nouso K, Nakatsukasa H, Yamano T, et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br J Cancer. 1999;81(6):1080–7.PubMedCrossRef
9.
Zurück zum Zitat Gunther FL, Hofbauer L, Schaefer C, Noppen C, Boni R, Kamarashev J, et al. MAGE-3 immunoreactivity in formalinfixed paraffin-embedded primary and metastatic melanoma. Am J Pathol. 1997;151:1549–53. Gunther FL, Hofbauer L, Schaefer C, Noppen C, Boni R, Kamarashev J, et al. MAGE-3 immunoreactivity in formalinfixed paraffin-embedded primary and metastatic melanoma. Am J Pathol. 1997;151:1549–53.
10.
Zurück zum Zitat Chen CH, Huang GT, Lee HS, Yang PM, Yan MD, Chen DS, et al. High genes frequency in human of expression of MAGE hepatocellular carcinoma. Liver. 1999;19:110–4.PubMedCrossRef Chen CH, Huang GT, Lee HS, Yang PM, Yan MD, Chen DS, et al. High genes frequency in human of expression of MAGE hepatocellular carcinoma. Liver. 1999;19:110–4.PubMedCrossRef
11.
Zurück zum Zitat Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999;85:1234–40.PubMedCrossRef Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer. 1999;85:1234–40.PubMedCrossRef
12.
Zurück zum Zitat Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J, Jiang J, et al. Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn. 2001;6(2):79–91.PubMedCrossRef Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J, Jiang J, et al. Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn. 2001;6(2):79–91.PubMedCrossRef
13.
Zurück zum Zitat Berois N, Varangot M, Aizen B, Estrugo R, Zarantonelli L, Fernández P, et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer. 2000;36(6):717–723. Berois N, Varangot M, Aizen B, Estrugo R, Zarantonelli L, Fernández P, et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer. 2000;36(6):717–723.
14.
Zurück zum Zitat Jiang SY, Shyu RY, Huang MF, Tang HS, Young TH, Roffler SR, et al. Detection of alphafetoprotein expressing cells in the blood of patients with hepatoma and hepatitis. Br J Cancer. 1997;75:928–33.PubMedCrossRef Jiang SY, Shyu RY, Huang MF, Tang HS, Young TH, Roffler SR, et al. Detection of alphafetoprotein expressing cells in the blood of patients with hepatoma and hepatitis. Br J Cancer. 1997;75:928–33.PubMedCrossRef
15.
Zurück zum Zitat Malek L, Jerome N, Herve Z, Abdelmajid S, Corinne V, Giovanna V, et al. Liver resection and needle liver biopsy cause hematogeneous dissemination of liver cells. Hepatology. 1999;29:879–82.CrossRef Malek L, Jerome N, Herve Z, Abdelmajid S, Corinne V, Giovanna V, et al. Liver resection and needle liver biopsy cause hematogeneous dissemination of liver cells. Hepatology. 1999;29:879–82.CrossRef
16.
Zurück zum Zitat Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, et al. Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group. J Hepatol. 1998;28(3):497–503. Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, et al. Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group. J Hepatol. 1998;28(3):497–503.
17.
Zurück zum Zitat Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg. 1997;226(1):43–50. Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg. 1997;226(1):43–50.
18.
Zurück zum Zitat Barbu V, Bonnand AM, Hillaire S, Coste T, Chazouilleres O, Gugenheim J, et al. Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology. 1997;26(5):1171–5.PubMed Barbu V, Bonnand AM, Hillaire S, Coste T, Chazouilleres O, Gugenheim J, et al. Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology. 1997;26(5):1171–5.PubMed
19.
Zurück zum Zitat Yuasa T, Okamoto K, Kawakami T, Mishina M, Ogawa O, Okada Y. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J Urol. 2001;165:1790–4.PubMedCrossRef Yuasa T, Okamoto K, Kawakami T, Mishina M, Ogawa O, Okada Y. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J Urol. 2001;165:1790–4.PubMedCrossRef
20.
Zurück zum Zitat Zhang Y, Li Q, Liu N, Song T, Guo R, Meng L, et al. Multimarker detection of MAGE-1, MAGE-3 and AFP mRNAs by a real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Chin J Clin Oncol. 2008;5:93–8.CrossRef Zhang Y, Li Q, Liu N, Song T, Guo R, Meng L, et al. Multimarker detection of MAGE-1, MAGE-3 and AFP mRNAs by a real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Chin J Clin Oncol. 2008;5:93–8.CrossRef
21.
Zurück zum Zitat Tsuzuraharsa S, Sata M, Iwamoto O, Shichijo S, Kojiro M, Tanikawa K, et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-c virus-associated hepatocellular carcinoma and liver cirrhosis. Jpn J Cancer Res. 1997;88:915–8.CrossRef Tsuzuraharsa S, Sata M, Iwamoto O, Shichijo S, Kojiro M, Tanikawa K, et al. Detection of MAGE-4 protein in the sera of patients with hepatitis-c virus-associated hepatocellular carcinoma and liver cirrhosis. Jpn J Cancer Res. 1997;88:915–8.CrossRef
22.
Zurück zum Zitat Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.PubMedCrossRef Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.PubMedCrossRef
23.
Zurück zum Zitat Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol. 2004;39:919–26.PubMedCrossRef Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol. 2004;39:919–26.PubMedCrossRef
Metadaten
Titel
MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma
verfasst von
Yousri M. Hussein
Amal F. Ghareib
Randa H. Mohamed
Mohamed I. Radwan
Wael H. Elsawy
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9917-9

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.